FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376106586> ?p ?o ?g. }

• W4376106586 abstract "BACKGROUND: To report the 3-year safety and effectiveness results of a multicenter, prospective, randomized controlled trial comparing the ZILVER PTX paclitaxel-eluting stent to surgical bypass and to conduct a health economic analysis up to 3-year follow-up of the two treatment modalities.METHODS: This is a study in symptomatic TransAtlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions comparing endovascular ZILVER PTX stenting vs. surgical bypass surgery using a prosthetic graft (ClinicalTrials.gov identifier NCT01952457). Between October 2013 and July 2017, 220 patients (mean age 68.6±10.5 years; 159 men) were enrolled and randomized to the ZILVER PTX treatment group (113, 51.40%) or the bypass treatment group (107, 48.60%). One of the secondary outcomes was primary patency at 3-year, defined as no evidence of binary restenosis or occlusion within the target lesion or bypass graft based on a duplex ultrasound peak systolic velocity ratio <2.4 and no clinically-driven target lesion revascularization (TLR) in endovascular cases or reintervention to restore flow in the bypass. An economic analysis was conducted to analyze the cost differences between ZILVER PTX and bypass, which shows the perspective of the public authority/organization that pays for healthcare in the two countries (payor), Germany and USA.RESULTS: The 3-year primary patency rate was 53.30% (95% CI 61.40% to 45.20%) for the ZILVER PTX group vs. 58.20% (95% CI 67.10% to 49.30%) for the bypass arm (P=0.9721). Freedom from TLR at 3-year was 62.80% (95% CI 72.60% to 53%) for the ZILVER PTX group vs. 65.30% (95% CI 75.40% to 55.20%) for the bypass group (P=0.635). There was also no significant difference (P=0.358) in survival rate at 3-year between the ZILVER PTX group 78.50%, (95% CI to 87.70% to 69.30%) and the bypass group 87.40% (95% CI 97.6% to 77.2%). None of the deaths was categorized as related to the procedure or device. The economic analysis, taking into account procedural-, hospitalization- and reintervention costs, showed a clear cost-benefit for Zilver PTX in both investigated countries up to 3-year follow-up: Germany (Bypass €9446 per patient versus ZILVER PTX €5755) and USA (Bypass $26,373 per patient versus ZILVER PTX $19,186).CONCLUSIONS: The non-inferior safety and effectiveness results of the ZILVER PTX stent were associated with lower costs for the payer and confirmed that ZILVER PTX stent treatment can be considered as a valid alternative for bypass surgery in long and complex femoropopliteal lesions." @default.
• W4376106586 created "2023-05-12" @default.
• W4376106586 creator A5006083917 @default.
• W4376106586 creator A5009379317 @default.
• W4376106586 creator A5009544053 @default.
• W4376106586 creator A5029710716 @default.
• W4376106586 creator A5037086471 @default.
• W4376106586 creator A5038098008 @default.
• W4376106586 creator A5047473208 @default.
• W4376106586 creator A5047565372 @default.
• W4376106586 creator A5051346274 @default.
• W4376106586 creator A5054958528 @default.
• W4376106586 creator A5054996768 @default.
• W4376106586 creator A5055523204 @default.
• W4376106586 creator A5059831121 @default.
• W4376106586 creator A5071921795 @default.
• W4376106586 creator A5073076864 @default.
• W4376106586 creator A5077635495 @default.
• W4376106586 creator A5091696448 @default.
• W4376106586 creator A5091917613 @default.
• W4376106586 date "2023-07-01" @default.
• W4376106586 modified "2023-10-02" @default.
• W4376106586 title "ZILVERPASS Study: ZILVER PTX Stent vs. Bypass Surgery in Femoropopliteal Lesions, 3 year results and economic analysis" @default.
• W4376106586 cites W1931807903 @default.
• W4376106586 cites W2045973896 @default.
• W4376106586 cites W2118304570 @default.
• W4376106586 cites W2136214453 @default.
• W4376106586 cites W2144985796 @default.
• W4376106586 cites W2179449978 @default.
• W4376106586 cites W2262125915 @default.
• W4376106586 cites W3003634243 @default.
• W4376106586 doi "https://doi.org/10.23736/s0021-9509.23.12607-3" @default.
• W4376106586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37162238" @default.
• W4376106586 hasPublicationYear "2023" @default.
• W4376106586 type Work @default.
• W4376106586 citedByCount "1" @default.
• W4376106586 countsByYear W43761065862023 @default.
• W4376106586 crossrefType "journal-article" @default.
• W4376106586 hasAuthorship W4376106586A5006083917 @default.
• W4376106586 hasAuthorship W4376106586A5009379317 @default.
• W4376106586 hasAuthorship W4376106586A5009544053 @default.
• W4376106586 hasAuthorship W4376106586A5029710716 @default.
• W4376106586 hasAuthorship W4376106586A5037086471 @default.
• W4376106586 hasAuthorship W4376106586A5038098008 @default.
• W4376106586 hasAuthorship W4376106586A5047473208 @default.
• W4376106586 hasAuthorship W4376106586A5047565372 @default.
• W4376106586 hasAuthorship W4376106586A5051346274 @default.
• W4376106586 hasAuthorship W4376106586A5054958528 @default.
• W4376106586 hasAuthorship W4376106586A5054996768 @default.
• W4376106586 hasAuthorship W4376106586A5055523204 @default.
• W4376106586 hasAuthorship W4376106586A5059831121 @default.
• W4376106586 hasAuthorship W4376106586A5071921795 @default.
• W4376106586 hasAuthorship W4376106586A5073076864 @default.
• W4376106586 hasAuthorship W4376106586A5077635495 @default.
• W4376106586 hasAuthorship W4376106586A5091696448 @default.
• W4376106586 hasAuthorship W4376106586A5091917613 @default.
• W4376106586 hasConcept C126322002 @default.
• W4376106586 hasConcept C126838900 @default.
• W4376106586 hasConcept C141071460 @default.
• W4376106586 hasConcept C168563851 @default.
• W4376106586 hasConcept C2776820930 @default.
• W4376106586 hasConcept C2778283817 @default.
• W4376106586 hasConcept C2778583881 @default.
• W4376106586 hasConcept C2779433084 @default.
• W4376106586 hasConcept C2780326628 @default.
• W4376106586 hasConcept C2780400711 @default.
• W4376106586 hasConcept C2781464078 @default.
• W4376106586 hasConcept C500558357 @default.
• W4376106586 hasConcept C71924100 @default.
• W4376106586 hasConceptScore W4376106586C126322002 @default.
• W4376106586 hasConceptScore W4376106586C126838900 @default.
• W4376106586 hasConceptScore W4376106586C141071460 @default.
• W4376106586 hasConceptScore W4376106586C168563851 @default.
• W4376106586 hasConceptScore W4376106586C2776820930 @default.
• W4376106586 hasConceptScore W4376106586C2778283817 @default.
• W4376106586 hasConceptScore W4376106586C2778583881 @default.
• W4376106586 hasConceptScore W4376106586C2779433084 @default.
• W4376106586 hasConceptScore W4376106586C2780326628 @default.
• W4376106586 hasConceptScore W4376106586C2780400711 @default.
• W4376106586 hasConceptScore W4376106586C2781464078 @default.
• W4376106586 hasConceptScore W4376106586C500558357 @default.
• W4376106586 hasConceptScore W4376106586C71924100 @default.
• W4376106586 hasIssue "4" @default.
• W4376106586 hasLocation W43761065861 @default.
• W4376106586 hasLocation W43761065862 @default.
• W4376106586 hasOpenAccess W4376106586 @default.
• W4376106586 hasPrimaryLocation W43761065861 @default.
• W4376106586 hasRelatedWork W2014930679 @default.
• W4376106586 hasRelatedWork W2036101787 @default.
• W4376106586 hasRelatedWork W2056861055 @default.
• W4376106586 hasRelatedWork W2066537135 @default.
• W4376106586 hasRelatedWork W2083268223 @default.
• W4376106586 hasRelatedWork W2085190579 @default.
• W4376106586 hasRelatedWork W2086794430 @default.
• W4376106586 hasRelatedWork W2111592624 @default.
• W4376106586 hasRelatedWork W2415092268 @default.
• W4376106586 hasRelatedWork W2574708060 @default.
• W4376106586 hasVolume "64" @default.
• W4376106586 isParatext "false" @default.
• W4376106586 isRetracted "false" @default.

• next